Bavarian Nordic vaccine sales go through the roof  

Smallpox vaccine sales to the US, UK and Germany put Bavarian Nordic on course for a USD 80 million annual turnover

Danish biotech company Bavarian Nordic has informed the Copenhagen Stock Exchange that high turnover has been generated in the first nine months of 2003 through sales of smallpox vaccines to the US, UK and Germany. Bavarian Nordic emerged from Q3 with earnings before interest and tax of close on DKK 193 million (USD 30.5 million) compared with a loss in the same period last year of DKK 65.2 million (USD 10.3 million). Turnover increased from a mere DKK 2.8 million (USD 442,000) to a mighty DKK 414 million (USD 65.4 million).


Bavarian Nordic forecasts a turnover of DKK 500 million (USD 79 million) for the accounting year 2003, while earnings before interest and tax are expected to be around DKK 250 million (USD 39.5 million). Since the new year the share price has risen by 110% and on an MAT basis has increased by no less than 221%. The news is reported by financial newspaper Børsen Online.


Link > Bavarian Nordic

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×